Related Experiment Video
Updated: Feb 5, 2026
12:16
Patient Derived Cell Culture and Isolation of CD133+ Putative Cancer Stem Cells from Melanoma
Published on: March 13, 2013
21.8K
RETRACTED: Aberrant Sialylation in Cancer Pathology and Metastasis, a Putative Drug Target Candidate
1Department of Cancer Pharmacology, Shanghai University, Shanghai 200444, China
Anti-Cancer Agents in Medicinal Chemistry
|September 13, 2018
Summary
This article on aberrant sialylation in cancer pathology and metastasis has been retracted due to author consent issues. The publication was an abuse of the scientific system.
Area of Science:
- Oncology
- Biochemistry
- Drug Discovery
Background:
- Aberrant sialylation is implicated in cancer pathology and metastasis.
- Sialylation represents a potential drug target for cancer therapies.
Purpose of the Study:
- To investigate the role of aberrant sialylation in cancer.
- To identify sialylation as a drug target candidate for cancer treatment.
Main Methods:
- The study involved analysis of sialylation patterns in cancer.
- Potential drug targets related to sialylation were explored.
Main Results:
- The article identified aberrant sialylation as a key factor in cancer progression.
- Sialylation was proposed as a promising therapeutic target.
Conclusions:
- Aberrant sialylation plays a significant role in cancer pathology and metastasis.
- Targeting sialylation pathways offers a potential strategy for cancer drug development.
Related Concept Videos
01:16Clot Retraction and Fibrinolysis
9.0K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
9.0K
02:57Targeted Cancer Therapies
8.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.9K
01:26Targets for Drug Action: Overview
10.3K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.3K
02:30Metastasis
6.6K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.6K
02:18Cancer
54.4K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
54.4K
01:25Pharmacokinetics: Drug–Drug Interactions
448
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
448